{"id":1888,"date":"2024-03-28T15:05:18","date_gmt":"2024-03-28T15:05:18","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1888"},"modified":"2024-03-28T15:05:19","modified_gmt":"2024-03-28T15:05:19","slug":"xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/","title":{"rendered":"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Strategic Reprioritization and Partnership with Gilead Sciences Propel Xilio&#8217;s Innovative Oncology Pipeline<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Xilio Therapeutics (XLO), a leading biotechnology firm specializing in tumor-activated immuno-oncology treatments, has announced a strategic reprioritization of its portfolio. The company is focusing on advancing clinical-stage programs for XTX301 and XTX101, two promising therapies targeting cancerous tumors. This decision follows the successful procurement of funds through a private investment in public equity financing, with an anticipated cash runway extending into the second quarter of 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The reprioritization involves leveraging the company&#8217;s innovative research platform for tumor-activated bispecific and cell engager molecules, aiming to maximize therapeutic efficacy in cancer treatment. Additionally, Xilio reported additional Phase 2 data for XTX202, supporting its potential as a combination therapy. Consequently, the company plans to discontinue monotherapy development and explore collaboration opportunities to further its development efforts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With a recent exclusive license agreement with Gilead Sciences for its tumor-activated IL-12 program, including XTX301, Xilio is poised for significant advancement in the field of cancer immunotherapy. This agreement provides substantial upfront payments, potential milestone payments, and royalties on future sales, further strengthening Xilio&#8217;s position in the oncology market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/home-depot-makes-historic-18-25-billion-acquisition-of-srs-distribution\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Home Depot Makes Historic $18.25 Billion Acquisition of SRS Distribution<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Strategic Reprioritization and Partnership with Gilead Sciences Propel Xilio&#8217;s Innovative Oncology Pipeline Xilio Therapeutics (XLO), a leading biotechnology firm specializing in tumor-activated immuno-oncology treatments, has announced a strategic reprioritization of its portfolio. The company is focusing on advancing clinical-stage programs for XTX301 and XTX101, two promising therapies targeting cancerous tumors. This decision follows the successful [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[308,358],"tags":[],"coauthors":[453],"class_list":["post-1888","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-micro-cap"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Strategic Reprioritization and Partnership with Gilead Sciences Propel Xilio&#8217;s Innovative Oncology Pipeline Xilio Therapeutics (XLO), a leading biotechnology firm specializing in tumor-activated immuno-oncology treatments, has announced a strategic reprioritization of its portfolio. The company is focusing on advancing clinical-stage programs for XTX301 and XTX101, two promising therapies targeting cancerous tumors. This decision follows the successful [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-28T15:05:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-28T15:05:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1706\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies\",\"datePublished\":\"2024-03-28T15:05:18+00:00\",\"dateModified\":\"2024-03-28T15:05:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/\"},\"wordCount\":210,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"articleSection\":[\"Biotechnology\",\"Micro-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/\",\"name\":\"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"datePublished\":\"2024-03-28T15:05:18+00:00\",\"dateModified\":\"2024-03-28T15:05:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"width\":2560,\"height\":1706,\"caption\":\"chemistry\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/28\\\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies - Stoxpo","og_description":"Strategic Reprioritization and Partnership with Gilead Sciences Propel Xilio&#8217;s Innovative Oncology Pipeline Xilio Therapeutics (XLO), a leading biotechnology firm specializing in tumor-activated immuno-oncology treatments, has announced a strategic reprioritization of its portfolio. The company is focusing on advancing clinical-stage programs for XTX301 and XTX101, two promising therapies targeting cancerous tumors. This decision follows the successful [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/","og_site_name":"Stoxpo","article_published_time":"2024-03-28T15:05:18+00:00","article_modified_time":"2024-03-28T15:05:19+00:00","og_image":[{"width":2560,"height":1706,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies","datePublished":"2024-03-28T15:05:18+00:00","dateModified":"2024-03-28T15:05:19+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/"},"wordCount":210,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","articleSection":["Biotechnology","Micro-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/","name":"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","datePublished":"2024-03-28T15:05:18+00:00","dateModified":"2024-03-28T15:05:19+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","width":2560,"height":1706,"caption":"chemistry"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/28\/xilio-therapeutics-secures-funding-for-clinical-advancement-of-cancer-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Xilio Therapeutics Secures Funding for Clinical Advancement of Cancer Therapies"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1888"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1888\/revisions"}],"predecessor-version":[{"id":1889,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1888\/revisions\/1889"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1888"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}